Leeds Teaching Hospitals NHS Trust, UK; University of Leeds, UK.
The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
Radiother Oncol. 2021 Nov;164:104-114. doi: 10.1016/j.radonc.2021.09.010. Epub 2021 Sep 21.
Stereotactic Ablative Radiotherapy (SABR) is increasingly used to treat metastatic oligorecurrence and locoregional recurrences but limited evidence/guidance exists in the setting of pelvic re-irradiation. An international Delphi study was performed to develop statements to guide practice regarding patient selection, pre-treatment investigations, treatment planning, delivery and cumulative organs at risk (OARs) constraints.
Forty-one radiation oncologists were invited to participate in three online surveys. In Round 1, information and opinion was sought regarding participants' practice. Guidance statements were developed using this information and in Round 2 participants were asked to indicate their level of agreement with each statement. Consensus was defined as ≥75% agreement. In Round 3, any statements without consensus were re-presented unmodified, alongside a summary of comments from Round 2.
Twenty-three radiation oncologists participated in Round 1 and, of these, 21 (91%) and 22 (96%) completed Rounds 2 and 3 respectively. Twenty-nine of 44 statements (66%) achieved consensus in Round 2. The remaining 15 statements (34%) did not achieve further consensus in Round 3. Consensus was achieved for 10 of 17 statements (59%) regarding patient selection/pre-treatment investigations; 12 of 13 statements (92%) concerning treatment planning and delivery; and 7 of 14 statements (50%) relating to OARs. Lack of agreement remained regarding the minimum time interval between irradiation courses, the number/size of pelvic lesions that can be treated and the most appropriate cumulative OAR constraints.
This study has established consensus, where possible, in areas of patient selection, pre-treatment investigations, treatment planning and delivery for pelvic SABR re-irradiation for metastatic oligorecurrence and locoregional recurrences. Further research into this technique is required, especially regarding aspects of practice where consensus was not achieved.
立体定向消融放疗(SABR)越来越多地用于治疗转移性寡复发和局部区域复发,但在盆腔再放疗中,证据/指南有限。进行了一项国际 Delphi 研究,以制定指导实践的声明,指导患者选择、治疗前检查、治疗计划、治疗实施以及累积危及器官(OAR)限制。
邀请了 41 名肿瘤放疗医师参加了三项在线调查。在第 1 轮中,征求了参与者实践方面的信息和意见。使用这些信息制定了指导声明,并在第 2 轮中要求参与者表示对每条声明的同意程度。共识定义为≥75%的同意率。在第 3 轮中,对于没有达成共识的任何声明,未作修改地重新呈现,并附有第 2 轮的评论摘要。
23 名肿瘤放疗医师参加了第 1 轮,其中 21 名(91%)和 22 名(96%)分别完成了第 2 轮和第 3 轮。第 2 轮中有 29 项(66%)声明达成共识。其余 15 项(34%)声明在第 3 轮中未达成进一步共识。在患者选择/治疗前检查方面,10 项(59%)声明达成共识;在治疗计划和实施方面,12 项(92%)声明达成共识;在 OAR 方面,7 项(50%)声明达成共识。在两次放疗之间的最小时间间隔、可治疗的盆腔病变数量和大小以及最合适的累积 OAR 限制方面,仍存在不一致的意见。
本研究在转移性寡复发和局部区域复发的盆腔 SABR 再放疗的患者选择、治疗前检查、治疗计划和实施方面,尽可能达成了共识。需要对这项技术进行进一步的研究,特别是在没有达成共识的实践方面。